2012
DOI: 10.1590/s1517-83822012000100043
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of immunity against avian colibacillosis induced by an aroA mutant containing increased serum survival gene in broilers

Abstract: Colibacillosis is an important disease in the poultry industry which causes serious economic damages. As it is suggested that vaccination is one of the means to control colibacillosis, we tried to investigate the vaccine potential of a ΔaroA derivative of an O78:K80 avian pathogenic Escherichia coli containing increased serum survival gene. 490 chicks were selected as follows: For assessment of virulence of ΔaroA mutant, 30 chicks were divided into three groups and injected with 0.5ml of PBS or bacte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
13
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(15 citation statements)
references
References 27 publications
(38 reference statements)
2
13
0
Order By: Relevance
“…Early attempts in APEC vaccines resulted only in protection against homologous challenge; that is, protection was only effective against the single strain that was used to create the vaccine [152,[161][162][163]. Effective vaccination whether by subunit vaccines, that target specific genetic virulence factors, or by live attenuated vaccines (LAV), have mostly resulted in coverage only against homologous challenge [164][165][166][167]. One commercially available LAV produced from nonpathogenic E. coli provides protection via cell-mediated immunity [168].…”
Section: Apec Vaccinesmentioning
confidence: 99%
“…Early attempts in APEC vaccines resulted only in protection against homologous challenge; that is, protection was only effective against the single strain that was used to create the vaccine [152,[161][162][163]. Effective vaccination whether by subunit vaccines, that target specific genetic virulence factors, or by live attenuated vaccines (LAV), have mostly resulted in coverage only against homologous challenge [164][165][166][167]. One commercially available LAV produced from nonpathogenic E. coli provides protection via cell-mediated immunity [168].…”
Section: Apec Vaccinesmentioning
confidence: 99%
“…Two-fold serial dilution of each serum sample was carried out using nine clean dry tubes containing a diluent of 0.9% w/v of NaCl sterile solution [21]. In the first tube 0.1 mL of serum was mixed with a 0.9 mL of diluent and then 0.5 mL of diluted serum was transferred to a second tube containing 0.5 mL of a diluent.…”
Section: Tube Agglutination Testmentioning
confidence: 99%
“…Each chicken was experimentally infected with a pathogenic strain of Escherichia coli. (E. coli O111:H4) by injection of 0.5 ml of the required concentration (10 7 micro-organism/ml) subcutaneously in the neck region of birds (Salehi et al, 2012). After appearance of the clinical symptoms of bacteraemia as fever and bloody diarrhea 48 hours post infection with Escherichia coli suspension, each infected bird was given marbofloxacin orally at dose rate of 2 mg/kg b.wt of once daily for five consecutive days.…”
Section: Experimental Designmentioning
confidence: 99%